Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Kraig Biocraft Laboratories (KBLB) EBITDA Margin (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed EBITDA Margin for 6 consecutive years, with 1278.64% as the latest value for Q4 2022.

  • Quarterly EBITDA Margin rose 129335114.0% to 1278.64% in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 548.5% through Dec 2022, down 31756.0% year-over-year, with the annual reading at 205.5% for FY2025, 37504.0% down from the prior year.
  • EBITDA Margin hit 1278.64% in Q4 2022 for Kraig Biocraft Laboratories, up from 1084.13% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1278.64% in Q4 2022 to a low of 1292072.5% in Q4 2021.
  • Historically, EBITDA Margin has averaged 128846.53% across 3 years, with a median of 342.47% in 2022.
  • Biggest YoY gain for EBITDA Margin was 129335114bps in 2022; the steepest drop was -17344bps in 2022.
  • Year by year, EBITDA Margin stood at 105.11% in 2018, then tumbled by -1229206bps to 1292072.5% in 2021, then surged by 100bps to 1278.64% in 2022.
  • Business Quant data shows EBITDA Margin for KBLB at 1278.64% in Q4 2022, 1084.13% in Q3 2022, and 347.85% in Q2 2022.